用于治疗渗出性年龄相关性黄斑变性和糖尿病性黄斑水肿的后节药物递送
本文综述血管内皮生长因子抑制剂治疗渗出性年龄相关性黄斑变性(AMD)和糖尿病性黄斑水肿(DME)时因需频繁玻璃体内注射而长期疗效受限的问题,讨论眼部屏障对药物渗透的挑战,并介绍相关药物递送平台的最新进展,包括已进入III期试验的端口递送系统及纳米颗粒等临床前研究。
要点
- 血管内皮生长因子抑制剂治疗渗出性AMD和DME的长期疗效受限于频繁且有创的玻璃体内注射需求。
- 多种技术在II期或III期试验中因过早失败而终止,但临床前研究显示纳米颗粒等可通过微创途径向后节递送治疗药物。
- 用于治疗渗出性AMD的端口递送系统已进入III期试验。
核心结论
- 尽管多种药物递送技术在II期或III期试验中过早失败,但临床前研究显示纳米颗粒等可通过微创途径向后节递送治疗药物,端口递送系统已进入III期试验。
研究设计与样本
- 本文为综述,讨论眼部屏障对药物渗透的挑战,并介绍最相关药物递送平台的最新进展,重点关注渗出性AMD和DME的治疗。
主要发现
- 血管内皮生长因子抑制剂虽有效,但长期疗效受限于需频繁且有创的玻璃体内注射。
- 多种递送技术在II期或III期试验中过早失败。
- 端口递送系统用于治疗渗出性AMD已进入III期试验。
- 脂质体、树枝状聚合物和细胞穿透肽等纳米颗粒的临床前研究显示可通过微创途径向后节递送治疗药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhibitors of vascular endothelial growth factors are used to treat a myriad of retinal conditions, including exudative age-related macular degeneration (AMD), diabetic macular oedema (DME) and diabetic retinopathy. Although effective, long-term efficacy is limited by the need for frequent and invasive intravitreal injections. The quest for sustained action therapeutics that can be delivered to target tissue in the least invasive manner is an arduous endeavour that has ended in premature failure for several technologies in Phase II or III trials. Nevertheless, there have been promising preclinical studies, and more are on the horizon: port delivery systems for the treatment of exudative AMD have entered Phase III trials and a wide array of preclinical studies have demonstrated the potential for nanoparticles, such as liposomes, dendrimers and cell penetrating peptides to deliver therapeutics into the posterior segment via minimally invasive routes. In this review, we discuss the challenges posed by ocular barriers for drug penetration and present the recent advancements of the most pertinent drug delivery platforms with a focus on the treatment of exudative AMD and DME.
引用
- Wong CW, Wong TT. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. Br J Ophthalmol. 2019. PMID: 31040133. doi:10.1136/bjophthalmol-2018-313462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。